+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine



Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine



Journal of Acquired Immune Deficiency Syndromes 38(2): 147-155



Comparisons of body composition and metabolic changes among antiretroviral-naive patients randomly assigned to didanosine and stavudine- (dd1 + d4T) vs. abacavir and lamivudine-(ABC + 3TC) containing regimens were assessed in a nested substudy of an ongoing multicenter randomized trial. At baseline and every 4 months, body cell mass and total body fat were calculated, anthropometric measurements were performed, and fasting metabolic parameters were obtained.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011814056

Download citation: RISBibTeXText

PMID: 15671799

DOI: 10.1097/01.qai.0000143599.64234.15


Related references

Abacavir, Didanosine and Stavudine versus Ritonavir, Saquinavir, Zidovudine and Lamivudine or Nelfinavir, Nevirapine, Zidovudine and Lamivudine in antiretroviral naive HIV patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 261, 2002

Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients. Antiviral Therapy 4(Suppl. 3): 71-74, 1999

Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons. HIV Clinical Trials 5(6): 361-370, 2005

Long-Term Subcutaneous Tissue Changes Among Antiretroviral-Naive Persons Initiating Stavudine, Zidovudine, or Abacavir With Lamivudine. Jaids Journal of Acquired Immune Deficiency Syndromes 48(1): 53-62, 2008

A phase II randomized study of the virologic and immunologic effect of zidovudine + stavudine versus stavudine alone and zidovudine + lamivudine in patients with >300 CD4 cells who were antiretroviral naive (ACTG 298). Aids Research and Human Retroviruses 18(10): 699-704, 2002

A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. Journal of Acquired Immune Deficiency Syndromes 27(2): 116-123, 2001

Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes 39(3): 257-264, 2005

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial). Antiviral Therapy 7(4): 293-303, 2002

A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients. Aids 14(10): 1375-1382, 2000

Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results. Aids Patient Care and Stds 24(6): 361-366, 2010

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 285(9): 1155-1163, 2001

Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients. Antiviral Therapy 4(Suppl. 3): 83-84, 1999

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. Bmc Infectious Diseases 13: 269, 2013

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naive, HIV-infected patients SUPPORT 96-week results. 2013

Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study. Current Therapeutic Research Clinical and Experimental 69(1): 90, 2008